Declaration of interest statement M Højlund has received honoraria/has been a consultant for Lundbeck and Otsuka. P Fusar-Poli is supported by #NEXTGENERATIONEU (NGEU), funded by the Ministry of University and Research (MUR), National Recovery and Resilience Plan (NRRP), project MNESYS (PE0000006) – A Multiscale integrated approach to the study of the nervous system in health and disease (DN. 1553 11.10.2022). CU Correll has been a consultant and/or advisor to or has received honoraria from: AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Biogen, Boehringer-Ingelheim, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Denovo, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Neurelis, Newron, Noven, Novo Nordisk, Otsuka, Pharmabrain, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Seqirus, SK Life Science, Sunovion, Sun Pharma, Supernus, Takeda, Teva, and Viatris. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Compass Pathways, Denovo, Lundbeck, Relmada, Reviva, Rovi, Sage, Supernus, Tolmar and Teva. He has received grant support from Janssen and Takeda. He received royalties from UpToDate and is also a stock option holder of Cardio Diagnostics, Mindpax, LB Pharma, Kuleon Biosciences and Quantic. M Solmi has received honoraria/has been a consultant for AbbVie, Angelini, Bausch Health, Boehringer Ingelheim, Lundbeck, Otsuka, and Teva. S Cortese has declared reimbursement for travel and accommodation expenses from the Association for Child and Adolescent Central Health (ACAMH) in relation to lectures delivered for ACAMH, the Canadian ADHD Alliance Resource, the British Association of Psychopharmacology, Healthcare Convention and CCM Group team for educational activity on ADHD, and has received honoraria from Medice. MI Husain has led contracted research for COMPASS Pathfinder Ltd., and provided consultancy to Mindset Pharma Inc., Psyhed Therapeutics, and Wake Network Inc. JD Rosenblat has received industry funding for speaker/consultation/research fees from iGan, Boehringer Ingelheim, Janssen, Braxia Health, Braxia Scientific, Allergan, Lundbeck, Sunovion and COMPASS. L Yatham has been a consultant and/or advisor to or has received honoraria from Allergan, Abbvie, Merck, Sanofi, Sumitomo Pharma, Sunovion, GSK, Gedeon Richter, Intracellular Therapies, Otsuka, Lundbeck, JAMA Pharma, received grant funding from Abbvie and Sumitomo Pharma and served on the Data Monitoring Board for Allergan and Alkermes. A Cipriani has received honoraria for lectures from Angelini Pharma and Lundbeck Pharma. AC is investigator of an early phase trial about seltorexant in adolescent depression (payment to my institution). D Moher is a member of the BMJ North American advisory committee. E Vieta has received grants and served as consultant, advisor or CME speaker for the following entities: AB-Biotics, AbbVie, Adamed, Alcediag, Angelini, Biogen, Beckley-Psytech, Biohaven, Boehringer-Ingelheim, Celon Pharma, Compass, Dainippon Sumitomo Pharma, Ethypharm, Ferrer, Gedeon Richter, GH Research, Glaxo-Smith Kline, HMNC, Idorsia, Johnson & Johnson, Lundbeck, Luye Pharma, Medincell, Merck, Newron, Novartis, Orion Corporation, Organon, Otsuka, Roche, Rovi, Sage, Sanofi-Aventis, Sunovion, Takeda, Teva, and Viatris, outside the submitted work. M Solmi has received honoraria/has been a consultant for AbbVie, Angelini, Bausch Health, Boehringer Ingelheim, Lundbeck, Otsuka, and Teva. Other authors have no conflicts of interest to disclose.
PubMed
Psychedelic Science